As published in JAMA Oncology, University of Toronto researchers have found that changes in the design of cancer drug trials after patient enrollment began appeared common and were left frequently unreported.  The researchers reviewed 101 clinical trials between 2010 and 2016. Follow the link for these interesting results.

Lead Research/Investigator

Daniel Shehelovich, MD, Medical Oncology fellow Prince Margaret Cancer Centre & University of Toronto

http://www.radonc.utoronto.ca/content/daniel-l%C3%A9tourneau
Source: Healio

Pin It on Pinterest